Home / PDA Letter / Full Article

New Trends, New Challenges for BET

by Jay Bolden, Eli Lilly and Company, and Ned Mozier, PhD, Pfizer

Published On Aug 27, 2018

Endotoxin testing for pharmaceutical production processes has seen a number of advances in recent years, among them discovery of recombinant Factor C (rFC) and development of the monocyte activation test (MAT). At the same time, data integrity has become an issue for various test modes.

The contents of "New Trends, New Challenges for BET" are available to PDA members. Please sign up or log in to read the full article.